TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2977177

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Metoclopramide + Naloxone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 13
Study: 29294844

Group type: EXPERIMENTAL
Intervention: Prior history of interpersonal violence (IPV)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Prior accident exposure
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Prior disaster exposure
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Female gender
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Physical injury to caregiver
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Concern about others' safety
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Age
Number of subjects: 2000
Study: 31070146

Group type: EXPERIMENTAL
Intervention: Intravenous benzylpenicillin
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intravenous Augmentin
Number of subjects: 26
Study: 28365000

Group type: EXPERIMENTAL
Intervention: Therapist-guided Internet-based CBT
Number of subjects: 94

Group type: COMPARATOR
Intervention: Wait-list group (WL)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 94
Study: 25476583

Group type: EXPERIMENTAL
Intervention: Parent Mentors (PMs) intervention, which includes information on Medicaid/CHIP eligibility, assistance with application submission, and help maintaining coverage.
Number of subjects: 329

Group type: COMPARATOR
Intervention: Control group receiving traditional Medicaid/CHIP outreach.
Number of subjects: 329
Study: 23949473

Group type: EXPERIMENTAL
Intervention: Computer-based training module (25-minute duration)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo training module
Number of subjects: 231
Study: 16790460

Group type: EXPERIMENTAL
Intervention: 400 mg albendazole given twice a year as part of child health services
Number of subjects: 27995

Group type: EXPERIMENTAL
Intervention: 400 mg albendazole given annually as part of child health services
Number of subjects: 27995
Study: 12491207

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TMP-SMZ plus azithromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TMP-SMZ plus fluconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylaxis against Pneumocystis carinii pneumonia, toxoplasmic encephalitis, and Mycobacterium avium complex bacteremia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylaxis against fungal and cytomegalovirus infections
Number of subjects: 0
Study: 10026458

Group type: EXPERIMENTAL
Intervention: PTSD patients
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Coping styles in PTSD patients
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Coping styles
Number of subjects: 139
Study: 8917132

Group type: EXPERIMENTAL
Intervention: Serotonin selective reuptake inhibitors (SSRIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2004546

Group type: EXPERIMENTAL
Intervention: Acemetacin (120 mg per day)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Indomethacin (100 mg per day)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Acemetacin
Number of subjects: 173
Study: 6319152

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30565906

Group type: EXPERIMENTAL
Intervention: Patients with apathy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patients without apathy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Apathy Evaluation Scale (quantitative measure of apathy)
Number of subjects: 60
Study: 27084887

Group type: EXPERIMENTAL
Intervention: PACAP38 4pmol/kg/min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PACAP38 6pmol/kg/min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PACAP38 8pmol/kg/min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PACAP38 (all doses)
Number of subjects: 6
Study: 24907899

Group type: EXPERIMENTAL
Intervention: Dementia patients
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 1440
Study: 23822566

Group type: EXPERIMENTAL
Intervention: Aripiprazole once monthly (400 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aripiprazole once monthly
Number of subjects: 60
Study: 21905596

Group type: EXPERIMENTAL
Intervention: Amoxiclav (co-amoxiclav) administered twice a day in 12 hour intervals
Number of subjects: 38
Study: 19702368

Group type: EXPERIMENTAL
Intervention: Promises manipulated in hypothetical scenarios (Study 1 and Study 2)
Number of subjects: 1382

Group type: EXPERIMENTAL
Intervention: Delivered inducements manipulated in hypothetical scenarios (Study 1 and Study 2)
Number of subjects: 1382

Group type: EXPERIMENTAL
Intervention: Longitudinal measurement of promises and delivered inducements (Study 3)
Number of subjects: 1382
Study: 17393787

Group type: EXPERIMENTAL
Intervention: recombinant human-growth hormone (rhGH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (routine treatment only)
Number of subjects: 40
Study: 14763918

Group type: EXPERIMENTAL
Intervention: Adiponectin measurement
Number of subjects: 297
Study: 11346729

Group type: EXPERIMENTAL
Intervention: Lidocaine (2%) with epinephrine (1:100,000)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Mepivacaine (3%)
Number of subjects: 17
Study: 9134509

Group type: EXPERIMENTAL
Intervention: Chorioamnionitis
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (gestation-matched women with preterm labor)
Number of subjects: 2
Study: 8200548

Group type: EXPERIMENTAL
Intervention: Daily omeprazole (20 mg every morning)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Weekend omeprazole (20 mg on three consecutive days a week)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Daily ranitidine (150 mg twice daily)
Number of subjects: 159
Study: 2828250

Group type: EXPERIMENTAL
Intervention: Sustained-release terbutaline (Bricanyl Retard) 5 mg b.i.d.
Number of subjects: 10
Study: 31742760

Group type: EXPERIMENTAL
Intervention: Feeding and eating disorders
Number of subjects: 27111
Study: 28914707

Group type: EXPERIMENTAL
Intervention: 10 minutes on/10 minutes off
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 30 minutes on/23.5 hours off
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 16 seconds on/8 seconds off
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Continuous
Number of subjects: 24

Group type: COMPARATOR
Intervention: All cycling settings
Number of subjects: 24
Study: 28821519

Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccinated women
Number of subjects: 15828

Group type: COMPARATOR
Intervention: Unvaccinated cohort
Number of subjects: 15828
Study: 26283884

Group type: EXPERIMENTAL
Intervention: Nefopam with oxycodone 1 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ketorolac with oxycodone 1 mg
Number of subjects: 120
Study: 24142738

Group type: EXPERIMENTAL
Intervention: Batifiban alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Batifiban coadministered with antithrombin agents
Number of subjects: 30

Group type: COMPARATOR
Intervention: Antithrombin agents alone (clopidogrel, aspirin, UFH)
Number of subjects: 30
Study: 20978529

Group type: EXPERIMENTAL
Intervention: Tailored modifications to food provision and dining environment over a 15-week period
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (no modifications)
Number of subjects: 156
Study: 18460488

Group type: EXPERIMENTAL
Intervention: KGM supplement (1.5 g, tid)
Number of subjects: 7
Study: 16570235

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System (CGMS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standardised self-monitoring blood glucose (SMBG) with CGMS
Number of subjects: 30
Study: 12643971

Group type: EXPERIMENTAL
Intervention: High responsibility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inflated responsibility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative mood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mood conditions
Number of subjects: 0
Study: 11053315

Group type: EXPERIMENTAL
Intervention: 6% glucose solution (CHO trial)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (Con trial)
Number of subjects: 13
Study: 9187991

Group type: EXPERIMENTAL
Intervention: 5% dextrose infusion at 250 mL/hr
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 5% dextrose infusion at 500 mL/hr
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control period (no infusion)
Number of subjects: 49
Study: 1329491

Group type: EXPERIMENTAL
Intervention: 0.4 mg naloxone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 4062714

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol powder (400 micrograms)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Inhaled fenoterol powder (200 micrograms)
Number of subjects: 40
Study: 31161692

Group type: EXPERIMENTAL
Intervention: Bexagliflozin (20 mg)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Sitagliptin (100 mg)
Number of subjects: 386
Study: 30048604

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises
Number of subjects: 97

Group type: COMPARATOR
Intervention: General information on menopause (Control)
Number of subjects: 97
Study: 26732120

Group type: EXPERIMENTAL
Intervention: Individualized program of muscular strength and endurance with aerobic training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25240757

Group type: EXPERIMENTAL
Intervention: VLP vaccines (H1 or H5) with 5-45 μg of HA/dose
Number of subjects: 280
Study: 22450873

Group type: EXPERIMENTAL
Intervention: 17-DMAG (36 mg/m²)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 17-DMAG (considering between-occasion variability)
Number of subjects: 67
Study: 19828561

Group type: EXPERIMENTAL
Intervention: cisplatin plus pemetrexed (CP; C, 75 mg/m(2) and P, 500 mg/m(2))
Number of subjects: 1725

Group type: COMPARATOR
Intervention: cisplatin plus gemcitabine (CG; C, 75 mg/m(2) and G, 1250 mg/m(2))
Number of subjects: 1725

Group type: EXPERIMENTAL
Intervention: cisplatin plus pemetrexed (CP)
Number of subjects: 1725

Group type: COMPARATOR
Intervention: cisplatin plus gemcitabine (CG)
Number of subjects: 1725
Study: 16969381

Group type: EXPERIMENTAL
Intervention: Hazelnut-enriched diet (40 g/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control diet (low-fat, low-cholesterol, high-carbohydrate)
Number of subjects: 15
Study: 15716196

Group type: EXPERIMENTAL
Intervention: hTRT
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: CK20
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: CD4
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Simultaneous evaluation of hTRT, CK20, CD4
Number of subjects: 205

Group type: COMPARATOR
Intervention: Simultaneous evaluation vs Urinary Cytology
Number of subjects: 205

Group type: COMPARATOR
Intervention: hTRT mRNA vs TRAP
Number of subjects: 205
Study: 11902607

Group type: EXPERIMENTAL
Intervention: Zinc acetate 0.1%
Number of subjects: 7

Group type: COMPARATOR
Intervention: Commercial mouthrinses (containing triclosan with fluoride, triclosan with sodium bicarbonate, and herbal components)
Number of subjects: 7
Study: 10617168

Group type: EXPERIMENTAL
Intervention: Levodopa/benserazide 100/25 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 8932681

Group type: EXPERIMENTAL
Intervention: Doxylamine succinate 7.5 mg by mouth four times a day (up to nine doses)
Number of subjects: 688

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 688
Study: 2345835

Group type: EXPERIMENTAL
Intervention: Streamlined trial design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-academic practitioners as investigators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modifications in organization and design of the Myocarditis Treatment Trial
Number of subjects: 0
Study: 7436066

Group type: EXPERIMENTAL
Intervention: Topical TAC (tetracaine 0.5%, adrenaline 1:2,000, cocaine 11.8%)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Lidocaine infiltration
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Topical TAC
Number of subjects: 158
Study: 29378197

Group type: EXPERIMENTAL
Intervention: GS-9620 (1 mg, 2 mg, and 4 mg, weekly for 12 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 26200467

Group type: EXPERIMENTAL
Intervention: mRDTs followed by ACT
Number of subjects: 15517

Group type: COMPARATOR
Intervention: Presumptive treatment with ACT
Number of subjects: 15517

Group type: EXPERIMENTAL
Intervention: mRDTs
Number of subjects: 15517
Study: 24153001

Group type: EXPERIMENTAL
Intervention: Nereu programme (8-month intensive family-based multi-component behavioural intervention)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Counselling (monthly physical health and eating habits session)
Number of subjects: 100
Study: 20226412

Group type: EXPERIMENTAL
Intervention: PCT copolymer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Icodextrin
Number of subjects: 30
Study: 18209140

Group type: EXPERIMENTAL
Intervention: Nasal wash with modified seawater solution (Physiomer) plus standard medication
Number of subjects: 401
Study: 16707980

Group type: EXPERIMENTAL
Intervention: Weaning products with a mixture of GOS/FOS (4.5 g daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control weaning products with maltodextrin
Number of subjects: 35

Group type: COMPARATOR
Intervention: GOS/FOS group vs Control group
Number of subjects: 35
Study: 11936740

Group type: EXPERIMENTAL
Intervention: Medication monitors with counseling based on monitor record
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication monitors without counseling based on monitor record
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple containers for medication
Number of subjects: 0
Study: 9829443

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 16

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 16
Study: 8536044

Group type: EXPERIMENTAL
Intervention: Closure of the peritendineum
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bone grafting of the patellar defect with cancellous bone
Number of subjects: 50
Study: 2679856

Group type: EXPERIMENTAL
Intervention: Combined treatment of potent and weak corticosteroid cream with habit-reversal treatment
Number of subjects: 45

Group type: COMPARATOR
Intervention: Corticosteroid cream alone (control group)
Number of subjects: 45
Study: 19897665

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 10117
Study: 396650

Group type: EXPERIMENTAL
Intervention: benzilonium bromide (Ulcoban prolongatum)
Number of subjects: 29

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29
Study: 31814516

Group type: EXPERIMENTAL
Intervention: Gratitude
Number of subjects: 0

Group type: COMPARATOR
Intervention: Happiness
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutrality
Number of subjects: 0
Study: 30954567

Group type: EXPERIMENTAL
Intervention: 30 mg/m2 doxorubicin-loaded nanoparticles
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: 20 mg/m2 doxorubicin-loaded nanoparticles
Number of subjects: 397

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 397
Study: 29059295

Group type: EXPERIMENTAL
Intervention: Modified Tandem Traction Bow Appliance (MTTBA)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Facemask (FM)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 76
Study: 26943947

Group type: EXPERIMENTAL
Intervention: USL255 (200 mg) sprinkled onto applesauce
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: USL255 beads diluted in Ketocal
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: USL255 beads diluted in deionized water
Number of subjects: 36
Study: 25151339

Group type: EXPERIMENTAL
Intervention: CuZnSOD activity and TAS levels in patients with TD
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: MDA levels in patients with TD
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: RBANS subscales of Visuospatial/Constructional in patients with TD
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: RBANS subscales of attention in patients with TD
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: CuZnSOD as a contributor to attention index of RBANS
Number of subjects: 113
Study: 22503488

Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable (LAI)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 19059858

Group type: EXPERIMENTAL
Intervention: Multiple-component physical activity program
Number of subjects: 544
Study: 17617857

Group type: EXPERIMENTAL
Intervention: Machine perfusion (MP)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Cold storage (CS)
Number of subjects: 415
Study: 15658903

Group type: EXPERIMENTAL
Intervention: Esophagectomy (transthoracic or transhiatal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended esophagectomy with three-field lymphadenectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy with or without radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Definitive chemoradiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salvage esophagectomy
Number of subjects: 0
Study: 12193521

Group type: EXPERIMENTAL
Intervention: Low birthweight children (LBW)
Number of subjects: 261
Study: 9464712

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (60 g daily containing 40 g isolated soy protein)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (casein, 60 g daily)
Number of subjects: 104
Study: 7622257

Group type: EXPERIMENTAL
Intervention: Pefloxacin (1,200 mg daily for 15 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chloramphenicol (2 g daily for 15 days)
Number of subjects: 60
Study: 2388013

Group type: EXPERIMENTAL
Intervention: Endosonic technique
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Balanced forces technique
Number of subjects: 15

Group type: COMPARATOR
Intervention: Step-back filing technique
Number of subjects: 15
Study: 842367

Group type: EXPERIMENTAL
Intervention: Closing of the eyes (experimental condition)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Reading a book (control condition)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Blindfolded (experimental condition)
Number of subjects: 7
Study: 31104873

Group type: EXPERIMENTAL
Intervention: 1500 mg of crystalline glucosamine sulfate once daily for 6 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional treatment protocol
Number of subjects: 42
Study: 28600466

Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study: 26193781

Group type: EXPERIMENTAL
Intervention: Quetiapine SR (25-mg starting dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (25-mg starting dose)
Number of subjects: 20
Study: 24640582

Group type: EXPERIMENTAL
Intervention: Physical therapy plus oral porcine relaxin (pRLX), 20 ug b.i.d for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical therapy alone
Number of subjects: 0
Study: 20666678

Group type: EXPERIMENTAL
Intervention: Adapalene-BPO combination gel
Number of subjects: 3855

Group type: COMPARATOR
Intervention: Adapalene
Number of subjects: 3855

Group type: COMPARATOR
Intervention: BPO
Number of subjects: 3855

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 3855
Study: 18762285

Group type: EXPERIMENTAL
Intervention: Palatable high-fat food words
Number of subjects: 99
Study: 18251440

Group type: EXPERIMENTAL
Intervention: HIIT (high intensity intermittent fin-swim training)
Number of subjects: 20

Group type: COMPARATOR
Intervention: MICT (moderate intensity continuous training)
Number of subjects: 20
Study: 15159322

Group type: EXPERIMENTAL
Intervention: Psychosocial telephone counseling (PTC) intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Affected with breast and/or ovarian cancer
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Higher levels of cancer-specific distress
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Greater perceptions of social support
Number of subjects: 66
Study: 11233465

Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 252
Study: 9726695

Group type: EXPERIMENTAL
Intervention: Vera/Tran (verapamil SR 180 mg/trandolapril 1 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Meto/HCTZ (metoprolol 100 mg/hydrochlorothiazide 12.5 mg)
Number of subjects: 51
Study: 7989857

Group type: EXPERIMENTAL
Intervention: Resource teachers' perceptions of collaborative roles
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Constraints on resource teachers' collaborative role performance
Number of subjects: 147
Study: 2661584

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Carrier solution
Number of subjects: 14
Study: 4461976

Group type: EXPERIMENTAL
Intervention: Group A (total body physical fatigue)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Group B (local physical fatigue)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Group C (rest)
Number of subjects: 75
Study: 29466961

Group type: EXPERIMENTAL
Intervention: Gamma Knife radiosurgery (GKRS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Whole brain radiation therapy (WBRT)
Number of subjects: 23
Study: 27221316

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 59
Study: 26542501

Group type: EXPERIMENTAL
Intervention: Intracoronary application of 4 mL of bioabsorbable cardiac matrix (BCM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 0
Study: 22978318

Group type: EXPERIMENTAL
Intervention: CarboCarrier® insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: NPH-insulin
Number of subjects: 0
Study: 20102675

Group type: EXPERIMENTAL
Intervention: Self-administered Food Frequency Questionnaire (FFQ) administered twice (FFQ1 and FFQ2)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Self-administered Food Frequency Questionnaire (FFQ)
Number of subjects: 158